Table 2 Relationship between baseline plasma proteins and baseline AD and aMCI.

From: Diagnostic and predictive power of plasma proteins in Alzheimer's disease: a cross-sectional and longitudinal study in China

Characteristics

B

S.E

Wald

df

p

OR

95% confidence interval

aMCI

 Education

 − 0.195

0.043

20.387

1

 < 0.001*

0.823

0.756–0.896

 NfL

 − 0.045

0.019

5.764

1

0.016

0.956

0.921–0.992

 Ptau181

0.049

0.083

0.346

1

0.556

1.050

0.893–1.235

 Aβ42

0.165

0.191

0.749

1

0.387

1.179

0.812–1.714

 Aβ40

0.011

0.009

1.433

1

0.231

1.011

0.993–1.029

 Aβ42/40

− 149.031

40.748

13.376

1

 < 0.001*

–

–

AD

 Education

− 0.142

0.040

12.760

1

 < 0.001&

0.867

0.082–0.938

 NfL

0.049

0.012

18.057

1

 < 0.001&

1.050

1.027–1.075

 Ptau181

0.078

0.060

1.706

1

0.192

1.081

0.962–1.216

 Aβ42

− 0.284

0.113

6.293

1

0.012&

0.753

0. 603–0.940

 Aβ40

0.012

0.007

3.163

1

0.075

1.012

0.999–1.026

 Aβ42/40

− 45.534

20.701

4.838

1

0.028&

0.763

0.415–0.538

  1. NC Normal controls, aMCI amnestic mild cognitive impairment, AD Alzheimer's disease, CHD Coronary heart disease, NfL neurofilament light, P‐tau181 phosphorylated tau 181, T‐tau total tau, Aβ42 amyloid‐β42, Aβ40 amyloid‐β40, Aβ42/40 amyloid‐β42/40, MoCA Montreal Cognitive Assessment.
  2. Data were presented as mean (standard deviation) or frequencies (%); Demographic and clinical characteristics were assessed using Fisher exact test across the whole group, and then Kruskal‐Wallis test was used to compare continuous variables between two groups (NC, aMCI, and AD). Significant differences were found in plasma biomarker concentrations after accounting for the effects of age, educational, sex, hypertension, diabetes, and hyperlipidemia.
  3. *Significantly different from aMCI, p < 0.05.
  4. &Significantly different from AD, p < 0.05.
Back to article page